The effect of decitabine on the expression and methylation of the PPP1CA, BTG2, and PTEN in association with changes in miR‐125b, miR‐17, and miR‐181b in NALM6 cell line
- 25 March 2019
- journal article
- research article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 120 (8) , 13156-13167
Abstract
Precursor B‐cell acute lymphoblastic leukemia (B‐ALL) is the most prevalent pediatric cancer. DNA methylation and changes in the microRNAs (miRNAs) expression are known to be important causes of B‐ALL. Decitabine as a DNA methyltransferase inhibitor agent is able to induce hypomethylation in several tumor suppressor genes. Much evidence has proven BTG2, PPP1CA, and PTEN act as tumor suppressor genes in many malignancies. In this case control study, the messenger RNA (mRNA) expression of PPP1CA, BTG2, and PTEN genes using quantitative real‐time polymerase chain reaction (rRT‐PCR) in Nalm6 cell line and five patients suffer from ALL with mean age 5.6 years were determined in compare with seven normal healthy donors age and sex matched. qRT‐PCR analysis revealed that the expression levels of PPP1CA, BTG2, and PTEN genes were significantly decreased in Nalm6 ([FC] = 0.46, [FC] = 0.046, [FC] = 0.54) and according to the Methylation‐specific PCR (MSP) analysis, these genes were hypermethylated in Nalm6. In next step, the effects of decitabine treatment on the methylation and expression of these genes in association with changes in miR‐125b, miR‐17, and miR‐181b expression levels were evaluated in optimal concentration 2.5 µM of decitabine. Our data showed that decitabine is able to restore the expression levels of aforementioned genes and downregulate expression levels of oncomiRs; including miR‐125b, miR‐17, and miR‐181b in Nalm6 cell line. Therefore, it seems that decitabine can be used as a potential drug for the first line treatment of patients with B‐ALL, but further in vivo investigation is necessary.Keywords
Funding Information
- Shiraz University of Medical Sciences (13912)
This publication has 33 references indexed in Scilit:
- BTG2: A rising star of tumor suppressors (Review)International Journal of Oncology, 2014
- MiR-125b promotes cell migration and invasion by targeting PPP1CA-Rb signal pathways in gastric cancer, resulting in a poor prognosisGastric Cancer, 2014
- A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemiaAmerican Journal of Hematology, 2014
- Differential expression of miR-17∼92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemiaLeukemia, 2013
- Epigenetic Regulation of Cell Signaling Pathways in Acute Lymphoblastic LeukemiaEpigenomics, 2013
- B-cell regulator of immunoglobulin heavy-chain transcription (Bright)/ARID3a is a direct target of the oncomir microRNA-125b in progenitor B-cellsLeukemia, 2012
- Differential MiRNA expression in childhood acute lymphoblastic leukemia and association with clinical and biological featuresLeukemia Research, 2012
- PPP1CA contributes to the senescence program induced by oncogenic RasCarcinogenesis, 2007
- Rapid Identification of Protein Phosphatase 1-binding Proteins by Mixed Peptide Sequencing and Data Base SearchingJournal of Biological Chemistry, 1998
- Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.Proceedings of the National Academy of Sciences of the United States of America, 1996